

Supplementary Figure

Fig. S1




Fig. S1. DHA-AST enables colonic enrichment of DHA in DN mice and has no effects on body weight or food intake. (A) Schematic diagram for the verification of colon-targeting effect of DHA-AST in KKAY mice; (B) DHA levels of DN mice in the small intestine, colon, colonic contents, and serum; (C) Body weight; (D) Food intake; All data are expressed as means \pm SD ($n=3-10$, n represents the number of independent biological replicates per group). $P < 0.05$ indicates significant differences among groups. $^{\dagger}P < 0.05$, DN/DHA+AST vs DN/DHA group; $^{\ddagger}P < 0.05$, DN/DHA-AST vs DN/DHA group; $^{\S}P < 0.05$, DN/DHA-AST vs DN/DHA+AST group. Abbreviations: Ctrl, control; DN, diabetic nephropathy; DHA, docosahexaenoic acid; AST, astaxanthin.

Fig. S2




Fig. S2. Supplementary analysis of metagenomics and metabolomics. (A) The *Firmicutes/Bacteroidetes* ratio derived from metagenomic analysis; (B) Differential abundance analysis of the top 20 most abundant genera at the genus level; (C) PLS-DA plot derived from metabolomic analysis and (D) OPLS-DA plot ($R^2X=0.519$, $R^2Y=0.994$, $Q^2=0.751$, $R^2Y-Q^2 < 0.3$); (E) Spearman correlation analysis of differential genera with trehalose levels and kidney injury phenotypes (UACR and fasting blood glucose) (*, $P < 0.05$; **, $P < 0.01$). All data are expressed as means \pm SD ($n=3-4$, n represents the number of independent biological replicates per group). $P < 0.05$ indicates significant differences among groups. $^\dagger P < 0.05$, DN/DHA+AST vs DN

group; ‡ $P < 0.05$, DN/DHA-AST vs DN group; § $P < 0.05$, DN/DHA-AST vs DN/DHA+AST group. Abbreviations: PLS-DA, partial least squares discriminant analysis; OPLS-DA, orthogonal projections to latent structures discriminant analysis; Other abbreviations are the same as in **Fig. S1**.

Fig. S3




Fig. S3. The effects of trehalose on body weight and food intake in DN mice. (A)

Body weight; **(B)** Food intake; All data are expressed as means \pm SD (n=10, n

represents the number of independent biological replicates per group). * $P < 0.05$

indicate significant differences among groups. Abbreviations are the same as in **Fig.**

S1.

Fig. S4




Fig. S4. HSP90AA1 may be a key target for trehalose in ameliorating renal fibrosis. (A) The mRNA expression of *Serpine1*, *Ctgf*, *Colla1* and *Fn1* in fibrotic GMCs induced by different concentrations of TGF- β 1; (B) PPI network diagram of 296

key target proteins for trehalose; (C) Three-dimensional binding model of trehalose interacting with HSP90AA1 (Green, overall backbone of HSP90AA1; red sticks, bound ligand trehalose; blue sticks, key ligand-interacting amino acid residues; yellow, α -helix functional domain; black numerals, atomic distances between ligand and residues.); The mRNA and protein levels of HSP90AA1 in DN mice with (D) DHA-AST and (E) trehalose; (F) The mRNA expression of *Hsp90aa1*; (G) The protein levels of HSP90AA1 after individual or combined treatment with *siHsp90aa1* (50 mM), trehalose (10 mg/mL), and rHSP90AA1 (100 ng/mL). *Gapdh* was used as the endogenous control gene for qRT-PCR analysis. GAPDH was employed as endogenous control genes for western blot analysis. Data are presented as means \pm SD (n=3-10, n represents the number of independent biological replicates per group). * $P < 0.05$ indicates significant differences among groups; **, $P < 0.01$; ***, $P < 0.001$. Abbreviations: PPI, protein-protein interaction; HSP90AA1, heat shock protein 90 alpha family class A member 1; *siHsp90aa1*, small interfering RNA targeting *Hsp90aa1*; rHSP90AA1, recombinant HSP90AA; siNC, negative control small interfering RNA; Other abbreviations are the same as in **Fig. S1**.

Fig. S5




Fig. S5. HSP90AA1 knockdown attenuated TGF-β1-induced injury and potentiated trehalose protection, which was reversed by recombinant HSP90AA1

supplementation. The protein levels of (A) HSP90AA1, (B) CTGF, and (C) α-SMA

were detected after individual or combined treatment with siHsp90aa1 (50 mM), TGF-

β1 (10 ng/mL), trehalose (10 mg/mL), and rHSP90AA1 (100 ng/mL). GAPDH,

Tubulin and β-actin was employed as endogenous control genes for western blot

analysis. Data are presented as means ± SD (n=3, n represents the number of

independent biological replicates per group). * $P < 0.05$ indicates significant differences

among groups; **, $P < 0.01$; ***, $P < 0.001$. Abbreviations: PPI, protein-protein

interaction; HSP90AA1, heat shock protein 90 alpha family class A member 1;

siHsp90aa1, small interfering RNA targeting Hsp90aa1; rHSP90AA1, recombinant

HSP90AA; siNC, negative control small interfering RNA; Other abbreviations are the

same as in Fig. S1

Supplementary Table

Table 1. Dietary ingredient composition of H100293G

Components	Weight Ratio (g%)	Weight (g)
Protein	20	-
Carbohydrates	64	-
Fat	7	-
Total	-	-
Casein	-	200
Cystine	-	3
Corn Starch	-	397
Maltodextrin	-	132
Sucrose	-	100
Cellulose	-	50
Soybean Oil	-	70
Mineral Premix M1003G	-	35
Vitamin Premix V1002	-	10
Choline Bitartrate	-	2.5
Antioxidant TBHQ (tert-Butylhydroquinone)	-	0.014
Total	-	1000

Table 2. Dietary ingredient composition of H10045

Components	Weight Ratio (g%)	Weight (g)
Protein	24	-
Carbohydrates	41	-
Fat	24	-
Total	-	-
Casein	-	233.06
Cystine	-	3.5
Corn Starch	-	84.83
Maltodextrin	-	116.53
Sucrose	-	201.36
Cellulose	-	58.26
Soybean Oil	-	29.13
Lard	-	206.84
Mineral Mixture M1002	-	11.65
Calcium Hydrogen Phosphate	-	15.15
Calcium Carbonate	-	6.41
Potassium Citrate	-	19.23
Vitamin Mixture V1001	-	11.56
Choline Bitartrate	-	2.33
Food Red Dye	-	0.058
Total	-	1000

Table 3. Gene primer sequence.

Gene Name	Primer Sequence5'-3'
<i>Il6</i> (Mus musculus)	F: CTGCATTGGCATGAGGTTTG R: TCAGAGGGATCTGTGTCTTCT
<i>Il1b</i> (Mus musculus)	F: AAATGCCACCTTTTGACAGTGATG R: GCAGCCCTTCATCTTTTGGG
<i>Tnf</i> (Mus musculus)	F: TTGTCTTAATAACGCTGATTTGGT R: GGGAGCAGAGGTTTCAGTGAT
<i>Ccl2</i> (Mus musculus)	F: TTAAAAACCTGGATCGGAACCAA R: GCATTAGCTTCAGATTTACGGGT
<i>Sele</i> (Mus musculus)	F: GGTGCATCTGGGGAAGTAGA R: CCAGAGACCCGAGGAGAGTT
<i>Nos2</i> (Mus musculus)	F: TGCCTCTCACTCTTCCTTGG R: CCCAAAGTGCTTCAGTCAGG
<i>Cybb</i> (Mus musculus)	F: CTTCTTGGGTCAGCACTGGC R: GCAGCAAGATCAGCATGCAG
<i>Nox4</i> (Mus musculus)	F: CTTGGTGAATGCCCTCAACT R: TTCTGGGATCCTCATTCTGG
<i>Ptgs2</i> (Mus musculus)	F: GCGACATACTCAAGCAGGAGCA R: AGTGGTAACCGCTCAGGTGTTG
<i>Serpine1</i> (Mus musculus)	F: AGGATCGAGGTAAACGAGAGC R: GCGGGCTGAGATGACAAA


<i>Ctgf</i> (Mus musculus)	F: TGACCTGGAGGAAAACATTAAGA R: AGCCCTGTATGTCTTCACACTG
<i>Tgfb1</i> (Mus musculus)	F: GACTCTCCACCTGCAAGACCAT R: GGGACTGGCGAGCCTTAGTT
<i>Colla1</i> (Mus musculus)	F: CGGATAGCAGATTGAGAACATCCG R: CGGCTGAGTAGGGAACACACA
<i>Acta2</i> (Mus musculus)	F: TAACCCTTCAGCGTTCAGC R: ACATAGCTGGAGCAGCGTCT
<i>Fn1</i> (Mus musculus)	F: CGGAGAGAGTGCCCCTACTA R: CGATATTGGTGAATCGCAGA
<i>Hsp90aa1</i> (Mus musculus)	F: CAGAGGCGGACAAGAACGACAAG R: GATCCTGTTGGCGTGCGTCTG
<i>HSP90AA1</i> (Homo sapiens)	F: CAGAGGCGGACAAGAACGACAAG R: GATCCTGTTGGCGTGCGTCTG
<i>Gapdh</i> (Mus musculus)	F: TGGTGAAGGTCGGTGTGAAC R: GCTCCTGGAAGATGGTGATGG
<i>siHsp90aa1</i> (Mus musculus)	ACTGTCATCACGAAGCATAAC





Table 4. Binding energies of trehalose with candidate protein targets.




Compound	Protein Target	Binding Energy (kcal/mol)
	HSP90AA1	-7.073
	STAT3	1.05
Trehalose	ESR1	-0.28
	SRC	1.47
	AKT1	-0.9

Abbreviation: HSP90AA1, heat shock protein 90 alpha family class A member 1; STAT3, signal transducer and activator of transcription 3; ESR1, Estrogen Receptor 1; SRC, SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase; AKT1, AKT Serine/Threonine Kinase 1.

Uncropped original WB images














Fig. 6

■ Ctrl
■ TGF-β1
■ TGF-β1+Trehalose



Original uncropped Western blot







Fig. 6

■ Ctrl
■ TGF-β1
■ TGF-β1+Trehalose



Original uncropped Western blot

